Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors-Reference-Cited by-同舟云学术

Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors

Published:2022-08-01 Issue:1 Volume:25 Page:984-992
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Cafuir Lorraine¹²,Estrin Adina³^ORCID,Chen Er⁴,Hinds David⁴^ORCID,Prince Patricia³^ORCID,Thorburn Jennifer³^ORCID,Mead Henry⁴^ORCID,Kempton Christine L.¹²^ORCID

Affiliation:

1. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

2. Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, USA

3. Scientific Engagement, Aetion, Inc, New York, NY, USA

4. BioMarin Pharmaceuticals, Inc, San Rafael, CA, USA

Funder

BioMarin Pharmaceuticals, Inc

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2102779

Reference27 articles.

1. Hemophilia A. Genetic and Rare Diseases Information Center (GARD) – an NCATS Program [Internet]. [cited 2021 Jun 17]. Available from: https://rarediseases.info.nih.gov/diseases/6591/hemophilia-a

2. Hemophilia A. [Internet]. National Hemophilia Foundation. [cited 2021 Jun 17]. Available from: https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-a.

3. WFH Guidelines for the Management of Hemophilia, 3rd edition

4. Research C for DE and FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors. FDA [Internet]. 2019. [cited 2021 Oct 13]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii.

5. Research C for DE and FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors. FDA [Internet]. 2019. [cited 2021 Oct 13]; Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies;Expert Review of Hematology;2024-09-12

2. The imperative to prevent joint bleeding in everyone living with hemophilia;Research and Practice in Thrombosis and Haemostasis;2024-02

3. Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors;Journal of Medical Economics;2023-04-17

4. The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste;Research and Practice in Thrombosis and Haemostasis;2023-02